Rufinamide

證據等級: L5

預測適應症: 5 個

One-Sentence Summary

Rufinamide is a sodium-channel modulating anticonvulsant with established clinical use in refractory epilepsy syndromes such as Lennox-Gastaut syndrome. The TxGNN model predicts it may be effective for febrile infection-related epilepsy syndrome (FIRES), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model-derived signal.

Quick Overview

Item	Content
Original Indication	Refractory epilepsy (Lennox-Gastaut syndrome and related syndromes) — based on known clinical use; no local licensing record available
Predicted New Indication	Febrile infection-related epilepsy syndrome (FIRES)
TxGNN Prediction Score	99.57% (rank 4939)
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action data for rufinamide is currently a data gap. Based on available information, rufinamide acts as a voltage-gated sodium channel modulator that prolongs the channel's inactive state, and it is clinically used for Lennox-Gastaut syndrome and other refractory epilepsies.

FIRES is an acute, severely refractory status epilepticus syndrome mechanistically associated with excessive sodium-channel-mediated cortical excitability. Since rufinamide's established mechanism targets exactly this pathway, there is a theoretical rationale for extending its use to FIRES, paralleling its existing role in other treatment-resistant epilepsy syndromes.

However, this rationale currently rests entirely on mechanistic plausibility and the TxGNN prediction score (0.996). No clinical trials, ICTRP records, or peer-reviewed literature currently support use of rufinamide specifically in FIRES.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Rufinamide is not currently marketed in Finland (0 authorizations on record), so no product/dosage-form details are available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is mechanistically plausible but has zero clinical trial or literature support (Evidence Level L5), and a Blocking data gap exists for package insert warnings/contraindications, which prevents any initial safety assessment (S1).

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently Blocking
Confirmed mechanism-of-action documentation from DrugBank
Clinical trial or case-report evidence specifically in FIRES
Drug-drug interaction data (currently not found)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.